3-MeO-PCMo
Chemical compound
- CA: Schedule I
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine
- 138873-80-0
- 132605908
- 58191437
- 96QW73BA62
- Interactive image
- COC1=CC(C2(N3CCOCC3)CCCCC2)=CC=C1
InChI
- InChI=1S/C17H25NO2/c1-19-16-7-5-6-15(14-16)17(8-3-2-4-9-17)18-10-12-20-13-11-18/h5-7,14H,2-4,8-13H2,1H3
- Key:BOGOEDFWPOXWQE-UHFFFAOYSA-N
3-MeO-PCMo is a dissociative anesthetic drug which is similar in structure to phencyclidine[1][2] and been sold online as a designer drug.[3][4] The inhibitory effect of 3-MeO-PCMo on the reduction in the density of the drebrin clusters by NMDAR stimulation with glutamic acid is lower than that of PCP or 3-MeO-PCP, with half maximal inhibitory concentration (IC50) values of 26.67 μM (3-MeO-PCMo), 2.02 μM (PCP) and 1.51 μM (3-MeO-PCP).[5]
See also
References
- ^ Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (April 2011). "New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats". Pharmacology, Biochemistry, and Behavior. 98 (2): 227–33. doi:10.1016/j.pbb.2010.12.019. PMID 21215770. S2CID 24650035.
- ^ Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (March 2020). "4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels". Psychopharmacology. 237 (3): 757–772. doi:10.1007/s00213-019-05412-y. PMID 31828394. S2CID 209169410.
- ^ Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (February 2018). "Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues". Drug Testing and Analysis. 10 (2): 272–283. doi:10.1002/dta.2213. PMID 28513099.
- ^ "3-MeO-PCMo". New Synthetic Drugs Database. Archived from the original on 2016-07-03. Retrieved 2016-02-09.
- ^ Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (September–October 2019). "Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay". Journal of Pharmacological and Toxicological Methods. 99: 106583. doi:10.1016/j.vascn.2019.106583. PMID 31082488.
- v
- t
- e
Antihistamines | |
---|---|
Antidepressants | |
Antipsychotics |
Antidepressants | |
---|---|
Antipsychotics | |
Others |
- Agomelatine
- Melatonin
- Ramelteon
- Tasimelteon
- Cannabidiol
- Cannabis
- Chlorophenylalkyldiols
- Diethylpropanediol
- Evoxine
- Fenadiazole
- Guaifenesin-related muscle relaxants
- Midaflur
- Opioids (e.g., morphine)
- Passion flower
- Scopolamine
- Trazodone
- UMB68
- Valnoctamide
This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e